GSK/Desano Tie-Up To Bring Large Dolutegravir Price Cuts
This article was originally published in PharmAsia News
Executive Summary
HIV drug Tivicay is expected to become cheaper in China under a recent manufacturing deal between ViiV and Desano. The Chinese firm expects to gain a 35% share of the global generic antiretroviral API supply market this year after patent licensing agreements with the Medicines Patent Pool.
You may also be interested in...
FDA Warning Letter Could Impact Zhejiang Medicine’s US Foray
Zhejiang Medicine has become the latest major Chinese API firm to be hit with a US FDA warning letter amid stepped up oversight of production facilities in China by the US regulator, which has led to a string of similar actions this year alone. But efforts are now being made both by Chinese manufacturers and by authorities in the two countries to ensure adherence to international standards.
FDA Warning Letter Could Hamper Zhejiang Medicine’s US Foray
A recent US FDA warning letter could affect efforts by major Chinese API firm Zhejiang Medicine to build its US business, amid falling North American exports from China and a string of similar warnings over the past few years. But efforts are being made both by Chinese manufacturers and by US and Chinese regulators to ensure adherence to international standards.
China’s First Home Grown Novel HIV Drug Shoots For Prime Time
With a fast-growing HIV population and reliance on older-generation treatments, China could become the next frontier for new antiretroviral drugs. Government support might see the country’s first novel locally developed, long-lasting injectable product take on the big names in the field.